ViiV Healthcare, GSK & Pfizer’s Global Specialist HIV Company, Reports P-III (LATITUDE) Study Results of Cabenuva (cabotegravir + rilpivirine) for HIV
Shots:
- The P-III (LATITUDE) study determines the safety & efficacy of Cabenuva (cabotegravir + rilpivirine), long-acting injectable antiretroviral treatment, for HIV/AIDS and other infectious diseases across the US
- In the study, patients facing challenges with prescribed ART (oral, daily) & showing viremia were screened and recruited to administer dolutegravir and bictegravir-based regimens, to suppress virus. The patients were then randomized to receive long-acting injectable ART, Cabenuva (Q4W), or continue with daily, oral ART (SoC)
- The interim review analysis, as per DSMB, confirmed the superior effectiveness of Cabenuva vs daily oral SoC and therefore recommended for all the eligible patients who should receive the same
Ref: GSK | Image: ViiV Healthcare
Related News:- ViiV Healthcare’s Cabenuva (cabotegravir, rilpivirine) Receives the US FDA’s Approval for Virologically Suppressed Adolescents with HIV
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
